Amyloid β (Human, 28-35)

<strong>Amyloid β (Human, 28-35)</strong>_x000D_ <strong>Catalog number:</strong> B2024032_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 802.04 g/mol_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> Amyloid beta peptide (Human, 28-35), Aβ (28-35), Amyloid beta fragment (28-35), Aβ peptide (28-35), Amyloid beta (28-35) fragment, Human amyloid beta (28-35), Aβ(28-35)_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. *Physiological Reviews*, 81(2), 741-766._x000D_ _x000D_ 2. Hardy, J., &amp; Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*, 297(5580), 353-356._x000D_ _x000D_ 3. Haass, C., &amp; Selkoe, D. J. (2007). Soluble and insoluble amyloid beta: a toxic duo. *Nature Reviews Neuroscience*, 8(2), 101-112._x000D_ _x000D_ 4. Karran, E., &amp; Walker, L. (2013). The amyloid cascade hypothesis: are we poised for success? *Nature Reviews Drug Discovery*, 12(10), 751-752._x000D_ _x000D_ 5. Selkoe, D. J. (2012). Alzheimer's disease: a central role for amyloid. *Nature Reviews Neuroscience*, 13(8), 494-504._x000D_ _x000D_ 6. Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature Reviews Neuroscience*, 12(12), 933-948._x000D_ _x000D_ 7. De Strooper, B., &amp; Karran, E. (2016). The cellular phase of Alzheimer's disease. *Cell*, 164(4), 603-615._x000D_ _x000D_ 8. Cummings, J. (2016). The role of biomarkers in Alzheimer's disease drug development. *Nature Reviews Drug Discovery*, 15(11), 751-752._x000D_ _x000D_ 9. Vellas, B., et al. (2013). Designing drug trials for Alzheimer's disease: the role of biomarkers. *Nature Reviews Drug Discovery*, 12(12), 877-878._x000D_ _x000D_ 10. Haeberlein, S. M., et al. (2019). The role of amyloid beta in Alzheimer's disease: a review. *Nature Reviews Neuroscience*, 20(12), 757-770._x000D_ <a href="Amyloid β">https://pubmed.ncbi.nlm.nih.gov/?term=Amyloid β</a>_x000D_ _x000D_ <strong>Products Related to Amyloid β (Human, 28-35) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>